CY1106987T1 - Υπερεκφραση επιθυμητων πρωτεϊνων σε ευκαρυωτικα κυτταρα που επιτελειται απο υπερεκφραση κυκλινης d1 - Google Patents
Υπερεκφραση επιθυμητων πρωτεϊνων σε ευκαρυωτικα κυτταρα που επιτελειται απο υπερεκφραση κυκλινης d1Info
- Publication number
- CY1106987T1 CY1106987T1 CY20071101438T CY071101438T CY1106987T1 CY 1106987 T1 CY1106987 T1 CY 1106987T1 CY 20071101438 T CY20071101438 T CY 20071101438T CY 071101438 T CY071101438 T CY 071101438T CY 1106987 T1 CY1106987 T1 CY 1106987T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cyclin
- protein
- interest
- overexpression
- nucleic acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 8
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract 2
- 230000002018 overexpression Effects 0.000 title 2
- 102000016736 Cyclin Human genes 0.000 title 1
- 108050006400 Cyclin Proteins 0.000 title 1
- 108090000259 Cyclin D Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108010019673 Darbepoetin alfa Proteins 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 102000008108 Osteoprotegerin Human genes 0.000 abstract 2
- 108010035042 Osteoprotegerin Proteins 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 229940039781 leptin Drugs 0.000 abstract 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- -1 OPG-Fc Chemical compound 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση αφορά ευκαρυωτικά κύτταρα χρήσιμα σε έκφραση πρωτεΐνης που περιλαμβάνουν (a) ενθεμένο νουκλεϊκό οξύ που κωδικοποιεί προϊόν γονιδίου κυκλίνης D και (b) ενθεμένο νουκλεϊκό οξύ που κωδικοποιεί πρωτεΐνη ενδιαφέροντος, όπου το προϊόν γονιδίου κυκλίνης D και η πρωτεΐνη ενδιαφέροντος εκφράζονται στο κύτταρο. Η εφεύρεση αφορά επίσης διαδικασία παραγωγής πρωτεΐνης ενδιαφέροντος, που περιλαμβάνει (a) ένθεση σε ευκαρυωτικό κύτταρο νουκλεϊκού οξέος που κωδικοποιεί προϊόν γονιδίου κυκλίνης D και νουκλεϊκού οξέος που κωδικοποιεί πρωτεΐνη ενδιαφέροντος, (b) καλλιέργεια του κυττάρου υπό συνθήκες που καθιστούν εφικτή την έκφραση της πρωτεΐνης ενδιαφέροντος, και (c) απομόνωση της πρωτεΐνης ενδιαφέροντος. Τα κύτταρα είναι κατά προτίμηση κύτταρα θηλαστικού, με τα κύτταρα CHO να προτιμούνται περισσότερο. Το προϊόν γονιδίου κυκλίνης D είναι κατά προτίμηση ανθρώπινης προέλευσης. Οι κατάλληλες πρωτεΐνες ενδιαφέροντος περιλαμβάνουν ερυθροποιητίνη (ΕΡΟ), οστεοπροτεγερίνη (OPG), OPG-Fc, λεπτίνη, Fc-λεπτίνη, και Πρωτότυπη Πρωτεΐνη Διέγερσης Ερυθροποίησης (NESP: Novel Erythropoiesis Stimulating Protein).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9608698P | 1998-08-11 | 1998-08-11 | |
| US09/371,309 US6210924B1 (en) | 1998-08-11 | 1999-08-10 | Overexpressing cyclin D 1 in a eukaryotic cell line |
| EP99942098A EP1105507B1 (en) | 1998-08-11 | 1999-08-11 | Overexpression of desired proteins in eukaryotic cells mediated by cyclin d1 overexpression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106987T1 true CY1106987T1 (el) | 2012-09-26 |
Family
ID=22255220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071101438T CY1106987T1 (el) | 1998-08-11 | 2007-11-08 | Υπερεκφραση επιθυμητων πρωτεϊνων σε ευκαρυωτικα κυτταρα που επιτελειται απο υπερεκφραση κυκλινης d1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6210924B1 (el) |
| EP (1) | EP1105507B1 (el) |
| JP (1) | JP4562915B2 (el) |
| KR (1) | KR100502701B1 (el) |
| CN (1) | CN1151263C (el) |
| AT (1) | ATE374827T1 (el) |
| AU (1) | AU747640B2 (el) |
| CA (1) | CA2338820C (el) |
| CY (1) | CY1106987T1 (el) |
| DE (1) | DE69937243T2 (el) |
| DK (1) | DK1105507T3 (el) |
| ES (1) | ES2291038T3 (el) |
| HU (1) | HU230247B1 (el) |
| PT (1) | PT1105507E (el) |
| WO (1) | WO2000009714A1 (el) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| AU2002316384A1 (en) * | 2001-06-26 | 2003-03-03 | Photomed Technologies, Inc. | Multiple wavelength illuminator |
| US7364736B2 (en) | 2001-06-26 | 2008-04-29 | Amgen Inc. | Antibodies to OPGL |
| KR100427299B1 (ko) * | 2001-08-10 | 2004-04-14 | 한국생명공학연구원 | 인체 골 재흡수 억제인자（ｈＯＰＧ）를 생산하는 재조합플라스미드 ｐＧＨＯＰＧ（ＫＣＴＣ １０１９ＢＰ） |
| EP2314316A1 (en) | 2002-04-05 | 2011-04-27 | Amgen, Inc | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| TWI289668B (en) | 2002-09-06 | 2007-11-11 | Amgen Inc | Therapeutic human anti-IL-1R1 monoclonal antibody |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| MX2009002748A (es) | 2006-09-13 | 2009-03-26 | Abbott Lab | Mejoras de cultivos celulares. |
| EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| EP2111412A2 (en) * | 2007-02-02 | 2009-10-28 | Amgen, Inc | Hepcidin and hepcidin antibodies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| AU2010321720B2 (en) | 2009-11-23 | 2017-03-02 | Amgen Inc. | Monomeric antibody Fc |
| US8962277B2 (en) * | 2010-07-05 | 2015-02-24 | Univeristät für Bodenkultur Wien | Production cell line |
| MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| WO2013169734A1 (en) | 2012-05-07 | 2013-11-14 | Amgen Inc. | Anti-erythropoietin antibodies |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| US10435464B1 (en) | 2014-09-05 | 2019-10-08 | Coherus Biosciences, Inc. | Methods for making recombinant proteins |
| MX2017003247A (es) | 2014-09-15 | 2017-11-30 | Amgen Inc | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. |
| CA2964313C (en) | 2014-10-15 | 2023-03-14 | Amgen Inc. | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
| CN105669863B (zh) | 2014-12-05 | 2019-09-13 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| JP6937309B2 (ja) | 2016-01-27 | 2021-09-22 | ジャスト−エヴォテック バイオロジックス、インコーポレイテッド | ハイブリッドプロモーターおよびその使用 |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| EP3576789A4 (en) | 2017-02-01 | 2020-11-25 | Centrymed Pharmaceuticals Inc. | MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES |
| CN110305211A (zh) | 2018-03-20 | 2019-10-08 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| MX2020011614A (es) | 2018-05-01 | 2020-12-09 | Amgen Inc | Anticuerpos con perfiles de glicanos modulados. |
| CN110655577A (zh) | 2018-06-13 | 2020-01-07 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| MX2021014931A (es) | 2019-06-07 | 2022-01-24 | Amgen Inc | Construcciones de union biespecificas con enlazadores selectivamente escindibles. |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP4161969A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Bispecific binding constructs |
| IL303205A (en) | 2020-12-03 | 2023-07-01 | Amgen Inc | IMMUNOGLOBULINE constructs with multiple binding domains |
| CN115141276A (zh) | 2021-03-31 | 2022-10-04 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
| EP4347654A1 (en) | 2021-06-04 | 2024-04-10 | Amgen Research (Munich) GmbH | T cell engager molecules and uses thereof |
| CN113698466B (zh) * | 2021-07-30 | 2023-07-14 | 山东农业大学 | Ccnd1在制备禽反转录病毒生产增强剂中的应用 |
| WO2024092033A1 (en) | 2022-10-26 | 2024-05-02 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| IL79176A (en) | 1985-06-20 | 1992-06-21 | Kirin Amgen Inc | Process for the recovery of erythropoietin from a fluid |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| KR100221066B1 (ko) | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
| JPH06117187A (ja) | 1992-10-08 | 1994-04-26 | Iseki Tory Tech Inc | シールド掘削機 |
| US5514571A (en) | 1993-08-05 | 1996-05-07 | University Technologies International Inc. | Cyclin D1 negative regulatory activity |
| US5521066A (en) | 1993-09-13 | 1996-05-28 | Bristol-Myers Squibb Company | Periplasmic membrane-bound system for detecting protein-protein interactions |
| EP0734438A4 (en) | 1993-12-17 | 1998-12-23 | Spinal Cord Society | METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| DK0865294T3 (da) | 1995-08-17 | 2004-06-28 | Amgen Inc | Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater |
| CA2358862A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| GB9608143D0 (en) * | 1996-04-19 | 1996-06-26 | Ver Nl Kanker Inst | Assay |
-
1999
- 1999-08-10 US US09/371,309 patent/US6210924B1/en not_active Expired - Lifetime
- 1999-08-11 JP JP2000565148A patent/JP4562915B2/ja not_active Expired - Lifetime
- 1999-08-11 DE DE69937243T patent/DE69937243T2/de not_active Expired - Lifetime
- 1999-08-11 AT AT99942098T patent/ATE374827T1/de active
- 1999-08-11 ES ES99942098T patent/ES2291038T3/es not_active Expired - Lifetime
- 1999-08-11 WO PCT/US1999/018213 patent/WO2000009714A1/en active IP Right Grant
- 1999-08-11 EP EP99942098A patent/EP1105507B1/en not_active Expired - Lifetime
- 1999-08-11 HU HU0103485A patent/HU230247B1/hu unknown
- 1999-08-11 KR KR10-2001-7001843A patent/KR100502701B1/ko not_active IP Right Cessation
- 1999-08-11 DK DK99942098T patent/DK1105507T3/da active
- 1999-08-11 CA CA002338820A patent/CA2338820C/en not_active Expired - Lifetime
- 1999-08-11 AU AU55546/99A patent/AU747640B2/en not_active Expired
- 1999-08-11 PT PT99942098T patent/PT1105507E/pt unknown
- 1999-08-11 CN CNB998118990A patent/CN1151263C/zh not_active Expired - Lifetime
-
2007
- 2007-11-08 CY CY20071101438T patent/CY1106987T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100502701B1 (ko) | 2005-07-22 |
| EP1105507A1 (en) | 2001-06-13 |
| JP4562915B2 (ja) | 2010-10-13 |
| ES2291038T3 (es) | 2008-02-16 |
| ATE374827T1 (de) | 2007-10-15 |
| DE69937243T2 (de) | 2008-07-03 |
| JP2003524378A (ja) | 2003-08-19 |
| HUP0103485A2 (hu) | 2002-01-28 |
| DE69937243D1 (de) | 2007-11-15 |
| US6210924B1 (en) | 2001-04-03 |
| EP1105507B1 (en) | 2007-10-03 |
| AU5554699A (en) | 2000-03-06 |
| KR20020013462A (ko) | 2002-02-20 |
| CN1151263C (zh) | 2004-05-26 |
| WO2000009714A1 (en) | 2000-02-24 |
| DK1105507T3 (da) | 2007-11-05 |
| CN1322253A (zh) | 2001-11-14 |
| WO2000009714A9 (en) | 2000-05-18 |
| HUP0103485A3 (en) | 2010-01-28 |
| HU230247B1 (hu) | 2015-11-30 |
| PT1105507E (pt) | 2007-12-07 |
| CA2338820A1 (en) | 2000-02-24 |
| CA2338820C (en) | 2005-10-18 |
| AU747640B2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106987T1 (el) | Υπερεκφραση επιθυμητων πρωτεϊνων σε ευκαρυωτικα κυτταρα που επιτελειται απο υπερεκφραση κυκλινης d1 | |
| MX9605542A (es) | Produccion de proteinas y liberacion de proteinas. | |
| TR199903234T2 (xx) | Erkek doku tercih edilen d�zenleyici b�lge ve kullan�m�. | |
| PT83242B (pt) | Processo para a preparacao de polipeptidos com propriedades bioimunologicas do factor estimulante da producao de colonias pluripotenciais de granulocitos | |
| FI885679A (fi) | Samuttryckning i eukariotiska celler. | |
| ATE400651T1 (de) | Verwendung von grünem fluoreszenzprotein | |
| YU83101A (sh) | Postupci i materijali za sinteze organskih proizvoda | |
| DK0749444T3 (da) | Human/dyre-faktor VIII-hybrid | |
| MX9206376A (es) | Liberacion de proteinas por terapia genica | |
| ATE278024T1 (de) | Methode zur herstellung von rekombinanten zellen | |
| DE69939901D1 (de) | Verfahren und materialien zur herstellung von glucosamin | |
| CY1112195T1 (el) | Μεθοδος παρασκευης ενος πεπτιδιου με pl πανω απο 8 ή κατω απο 5 | |
| Baker et al. | Subunit structure and gene control of mouse NADP—malate dehydrogenase | |
| DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
| DE69728415D1 (de) | Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2) | |
| JP2023542976A (ja) | カーゴヌクレオチド配列を転位させるための系および方法 | |
| CY1105778T1 (el) | Γονιδιο του streptomyces avermitilis που κατευθυνει την αναλογια των αβepμεκτινων β2:β1 | |
| HUP0101961A2 (hu) | Az FSH-béta-gén módosítása homológ rekombinációval | |
| CY1112491T1 (el) | Γονιδιο streptomyces avermitilis που ελεγχει την αναλογια αβερμεκτινων β2:β1 | |
| AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
| Crampton et al. | A cell-free assay system for the analysis of changes in RNA synthesis during the development of Xenopus laevis | |
| ATE413451T1 (de) | Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren | |
| ATE451469T1 (de) | In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten | |
| Brachet | Biochemical changes during fertilization and early embryonic development | |
| CO4790179A1 (es) | Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena |